Oncology

The NK cell therapy is also being evaluated in a phase 1 study for acute myeloid leukemia.

The professor of medicine at Duke University School of Medicine previously served as commissioner in 2016.

The hematologist from Ohio State University Comprehensive Cancer Center–The James discussed the impact of socioeconomic factors on completion of autologous stem cell transplant in patients with mantle cell lymphoma.

Overall survival was 72% at 12 months but dropped to 54% at 14.6 months.

The request aims to ensure the comparability of omidubicel manufactured at different sites.

The director of Lymphoma Clinical Research at the University of Texas MD Anderson Cancer Center, discussed the future of DLBCL treatment.

A single administration of LN-145 monotherapy resulted in an overall response rate of 21.4% in patients with immunotherapy pretreated metastatic non–small cell lung cancer.

Review top news and interview highlights from the week ending November 12, 2021.

The first in-human study of CAR macrophages has dosed 2 participants so far.

The associate professor of medicine from MD Anderson Cancer Center discussed data from the phase 1 cohort of liso-cel combined with ibrutinib.

The BASECAMP-1 study is identifying patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) for future use of these therapies.

Three patients dosed had tumors shrinkages of 18%, 21%, and 27%.

The hematologist from Moffitt Cancer Center discussed the FDA approval of brexucabtagene autoleucel in relapsed/refractory B-cell acute lymphoblastic leukemia.

Data from the IMA203 trial were presented at the SITC 2021 annual meeting.

Sonny Hsiao, PhD, chief executive officer, president and cofounder, Acepodia, discussed the company’s future research and plans.

The director of Myeloma Immunotherapy at University of Pennsylvania discussed ciltacabtagene autoleucel's safety profile.

TCR² Therapeutics is collaborating with Bristol Myers Squibb to evaluate combination therapies in a phase 2 trial.

The hematologist and oncologist from UCSF Helen Diller Family Comprehensive Cancer Center discussed the potential utility of natural killer cells in multiple myeloma.

Yazeed Sawalha, MD, hematologist, Ohio State University Comprehensive Cancer Center, discussed how socioeconomic factors can affect use of ASCT in mantle cell lymphoma.

Autologous hematopoietic stem-cell transplantation maintained its long-term efficacy over interferon alfa in patients with mantle cell lymphoma.

A new project is manufacturing a “purified” version of CAR-T-cells currently used to treat types of lymphoma and leukemia.

The professor from University of Texas MD Anderson Cancer Center discussed the real-world efficacy of the first CAR T therapy for the treatment of mantle cell lymphoma.

Review top news and interview highlights from the week ending November 5, 2021.

The hematological oncologist from University of Chicago Medicine discussed chimeric antigen receptor T cells therapy in non-Hodgkin lymphoma.

Dipenkumar Modi, MD, discussed novel treatment options in leukemias and lymphomas.

The director at Dana-Farber Cancer Institute discussed future efforts to prevent the development of multiple myeloma.

The FDA also accepted a Type II Variation for the use of tisagenlecleucel in patients with R/R FL following 2 prior lines of treatment.

Paul Lammers, MD, MSc, president and chief executive officer, Triumvira Immunologics, discussed the challenges of manufacturing cell therapies.

The FDA has pushed cilta-cel's BLA PDUFA date back by almost 4 months.

The vaccination therapy improved progression-free survival by 3.1 months over standard care in 1 patient treated.